Drug profile · INN
piperacetazine
QUIDE
piperacetazine (QUIDE) is a dopamine d2 receptor antagonist. Route of administration: oral. Current US regulatory status: approved.
Drug details — piperacetazine
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 6
- Programs
- 6
- Data quality
- 0.84
Quick answer
piperacetazine (QUIDE) is a dopamine d2 receptor antagonist. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Dopamine D2 receptor antagonist
Primary target: D(2) dopamine receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
WO 2026013310
COMPOSITION PHARMACEUTIQUE LIQUIDE À BASE DE STIRIPENTOL
granted -
WO 2025219169
PRÉPARATIONS STABLES EN CAPSULES SOUPLES AVEC REMPLISSAGE LIQUIDE POUR PRINCIPES ACTIFS SENSIBLES À L'HUMIDITÉ
granted -
CA 3200144
COMPOSITIONS NUTRITIONNELLES LIQUIDES AVEC FLAVONOIDE VEGETAL INSOLUBLE DANS L'EAU ET PROCEDE POUR LEUR PRODUCTION
granted -
CA 3129357
FORMULATIONS PHARMACEUTIQUES LIQUIDES DE CONJUGUES PTH
granted -
WO 2020074463
COMPOSITION LIQUIDE ORALE COMPRENANT DU TRIPTAN
granted -
CA 3079530
COMPOSITION LIQUIDE STABLE DE KETOPROFENE, SELS ET ENANTIOMERES DE CELUI-CI
granted
Frequently asked questions
What is piperacetazine?
piperacetazine (QUIDE) is a dopamine d2 receptor antagonist. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for piperacetazine?
QUIDE is a marketed brand name for piperacetazine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of piperacetazine?
piperacetazine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.